# US 2014/0350527 A1 · "Self-Regulating Device for Modulating Inflammation"

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0350527 A1
- Document ID: US20140350527A1
- Status: Published application
- Kind: A1
- Application number: 14/301,734
- Filed: 2014-06-11
- Published: 2014-11-27
- Earliest claimed: 2008-09-29
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education
- Inventors: Yoram Vodovotz; Alexey Solovyev; David Okonkwo; Maxim Mikheev; Qi Mi; Jorg Gerlach; Gregory M Constantine
- Web page: https://patentgrep.com/patent/US20140350527A1

## CPC

- A61M 1/3489: {by biological cells, e.g. bioreactor}
- A61M 1/3472: {with treatment of the filtrate}
- A61M 1/3482: {by filtrating the filtrate using another cross-flow filter, e.g. a membrane filter}
- A61M 1/367: {Circuit parts not covered by the preceding subgroups of group A61M1/3621}
- A61M 1/95: {with sensors for exudate composition}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- B01D 63/026: {Wafer type modules or flat-surface type modules}
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)

## Abstract

A bioreactor is provided which contains cells capable of producing cytokine inhibitors in response to cytokines, in a manner regulated by the local or systemic milieu of an individual patient and predicted by mechanistic computational simulations. The bioreactor transfers the cytokine inhibitors to a patient in need of control of the inflammation process as part of a disease or condition in the patient, such as sepsis, trauma, traumatic brain injury, or wound healing. Related methods also are provided.

## Claims

### Claim 1

A method of modulating wound healing, sepsis, trauma, or traumatic brain injury (TBI), comprising,
providing bodily fluid of a patient to an extracorporeal bioreactor, wherein the extracorporeal bioreactor comprises:
a compartment comprising cells and a selectively permeable membrane in contact with the cells that does not permit passage of the cells and which permits passage of a first cytokine in the bodily fluid of the patient, the cells comprising a chimeric gene comprising a response element operably linked to a sequence encoding a second cytokine or a cytokine inhibitor, in which the response element causes expression of the second cytokine or cytokine inhibitor when the cells are contacted with the first cytokine in the bodily fluid of the patient;
contacting the bodily fluid with the selectively permeable membrane, such that the first cytokine in the bodily fluid can pass through the selectively permeable membrane and the second cytokine or cytokine inhibitor produced by the cells can pass into the bodily fluid; and
returning the bodily fluid to the patient.

### Claim 2 (depends on 1)

The method of claim 1, in which the cells are selected by use of a computer model of an inflammatory response characteristic of a disease or condition in the patient.

### Claim 3 (depends on 1)

The method of claim 1, comprising modeling inflammation associated with sepsis and determining one or more cytokines to inhibit or produce to control inflammation in the patient associated with sepsis.

### Claim 4 (depends on 3)

The method of claim 3, comprising determining levels of one or more cytokines in the patient and modeling inflammation using the one or more levels of cytokines in the patient and determining a cytokine level to be controlled in the patient to determine a chimeric gene construct to place in the bioreactor based on an outcome of the modeling.

### Claim 5 (depends on 4)

The method of claim 4, comprising modeling inflammation associated with TBI and determining one or more cytokines to inhibit or produce to control inflammation in the patient associated with TBI.

### Claim 6 (depends on 5)

The method of claim 5, comprising determining levels of one or more cytokines in the patient and modeling inflammation using the one or more levels of cytokines in the patient and determining a cytokine level to be controlled in the patient to determine a chimeric gene construct to place in the bioreactor based on an outcome of the modeling.

### Claim 7 (depends on 1)

The method of claim 1, in which the patient is a TBI patient.

### Claim 8 (depends on 7)

The method of claim 7, in which one or both of an inhibitor of TNF and an inhibitor of IL-6 are produced by the cells.

### Claim 9 (depends on 1)

The method of claim 1, in which the chimeric gene expresses a cytokine inhibitor selected from the group consisting of soluble TNF receptor, IL-1 receptor agonist, and TGF-β1 LAP (latency-associated peptide).

### Claim 10 (depends on 1)

The method of claim 1, in which the cells comprise one or more genes that express an inhibitor of one or both of TNF and IL-1α or IL-1β.

### Claim 11 (depends on 1)

The method of claim 1, in which the cells comprise one or more genes that express one or both of soluble TNF receptor and IL-1 receptor agonist.

### Claim 12 (depends on 1)

The method of claim 1, in which the compartment comprising the cells comprises a plurality of selectively permeable hollow fibers passing through the compartment in which the plurality of hollow fibers are fluidly connected to a plasma or blood circulation system in which blood or plasma from the patient is circulated through the hollow fibers and into the patient.

### Claim 13 (depends on 1)

The method of claim 1, in which the compartment comprising the cells has at least one wall that is the selectively permeable membrane, in which the selectively permeable membrane is placed in contact with a wound on the patient or a bodily fluid in situ in the patient.

### Claim 14 (depends on 13)

The method of claim 13, in which the compartment comprising the cells comprises a plurality of selectively permeable hollow fibers passing through the compartment through which one or both of a gas and a fluid comprising nutrients for the cells is passed.

### Claim 15 (depends on 1)

The method of claim 1, in which the cells are hepatic cells.
